AS-101 is under clinical development by Feramda and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AS-101’s likelihood of approval (LoA) and phase transition for Age Related Macular Degeneration took place on 05 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AS-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AS-101 (CB-06-02) is under development for the treatment of age-related macular degeneration, genital warts caused by HPV. It is a new chemical entity. The drug candidate is administered through oral, intraperitoneal, intravenous and topical routes. The therapeutic candidate is a synthetic tellurium compound. It acts by inhibiting IL-1 beta converting enzyme. It was also under development for the treatment of epilepsy, amyotrophic lateral sclerosis, Parkinson's disease, West Nile virus infections, atopic dermatitis, ischemic stroke, thrombocytopenia in solid tumour patients, HIV / AIDS, psoriasis and solid tumour, acute myelocytic leukaemia, chemotherapy-induced myelosuppression, myelodysplastic syndrome and chemotherapy-induced infertility.
Quick View AS-101 LOA Data
|Highest Development Stage|